Friday, March 31, 2023 12:06:34 PM
Japans interest in CBD patent
More accurately: "CVSI's interest in Japan's CBD market"
In either case, CV Sciences can barely afford a plane ticket to Japan, let alone the big bucks required to develop a pharmaceutical for ANY market.
Dowling acknowledged as much in the 2022Q4/Annual Earnings Call:
. . . while we have paused development of this [CVSI-007] program internally, we are seeking collaboration partners on this program.
I suspect that finding "collaboration partners" for funding the development of CVSI-007, which must compete with inexpensive OTC products, will be . . . difficult.
As for Japan, specifically:
Recent CVSI News
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
